Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Выбор блокаторов кальциевых каналов при артериальной гипертензии. Фармакокинетические и фармакодинамические механизмы высокой селективности и сверхдлительности действия лерканидипина
Выбор блокаторов кальциевых каналов при артериальной гипертензии. Фармакокинетические и фармакодинамические механизмы высокой селективности и сверхдлительности действия лерканидипина
Морозова Т.Е., Вартанова О.А. Выбор блокаторов кальциевых каналов при артериальной гипертензии. Фармакокинетические и фармакодинамические механизмы высокой селективности и сверхдлительности действия лерканидипина. Consilium Medicum. 2017; 19 (12): 59–65. DOI: 10.26442/2075-1753_19.12.59-65
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В обзоре представлены данные об эффективности, плейотропных эффектах и безопасности нового блокатора кальциевых каналов лерканидипина в лечении артериальной гипертензии. Препарат является высокоселективным липофильным блокатором L-каналов, длительность действия обеспечивается его медленным накоплением в билипидных мембранах клеток, что не вызывает активации симпатоадреналовой системы. Лерканидипин обладает органопротективным действием, уменьшает гипертрофию левого желудочка, улучшает функцию почек и оказывает антипротеинурическое действие, имеет хороший профиль безопасности, реже вызывает периферические отеки по сравнению с другими дигидропиридинами, хорошо сочетается с приемом других препаратов.
Ключевые слова: артериальная гипертензия, антигипертензивная терапия, дигидропиридиновые блокаторы кальциевых каналов, лерканидипин.
Key words: arterial hypertension, antihypertension therapy, dihydropyridine blockers of calcium channels, lercanidipine.
Ключевые слова: артериальная гипертензия, антигипертензивная терапия, дигидропиридиновые блокаторы кальциевых каналов, лерканидипин.
________________________________________________
Key words: arterial hypertension, antihypertension therapy, dihydropyridine blockers of calcium channels, lercanidipine.
Полный текст
Список литературы
1. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertension 2013; 1281–13.
2. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press 1996; 5: S206–8.
3. Epstein M. Role of a third generation calcium antagonists in the management of hypertension. Drugs 1999; 57 (Suppl. 1): S1–10.
4. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26–30.
5. Barchielli M, Dolfini E, Farina P et al. Clinical pharmacokinetics of lercanidipine. J Cardiovascul Pharmacol 1997; 29 (Suppl. 2): S1–S15.
6. Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract no. P1.191]. J Hypertens 2000; 18 (Suppl. 2): S65.
7. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): S236–253.
8. McClellan KJ, Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.
9. Licher ThF, Cosebtino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998; 55 (4): S309–17.
10. Triggle DJ. Mechanisms of action of calcium channel antagonists. In: Calcium antagonists in clinical medicine. Ed. by M.Epstein. Philadelphia 1998; S1–26.
11. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovascul Pharmacol 1997; 29 (Suppl. 1): S19–S24.
12. Van Zweiten PA, Pfaffendorf M. Pharmacology of dihydropyridine calcium antagonists; Relatiomship between lipophilicity and pharmacodynamic response. J Hypertension 1993; 11 (Suppl. 6): S3–S11.
13. S’anchez A, Sayans R, Alvarez JL et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract №12]. Fourth European Meeting on Calcium Antagonists; 1999 Oct 27–29; Amsterdam.
14. Bang LM, Chapman TM, Goa KL. (New Zealand.) Лерканидипин: обзор эффективности в терапии артериальной терапии. Drugs 2003; 63 (22): 2449–72. / Bang LM, Chapman TM, Goa KL. (New Zealand.) Lerkanidipin: obzor effektivnosti v terapii arterial'noi terapii. Drugs 2003; 63 (22): 2449–72. [in Russian]
15. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): S95–100.
16. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31–5.
17. Romito R, Pansini MI, Perticone F et al. Comparative effect of oflercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): S249–53.
18. Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50–3.
19. James IGV, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16 (8): S605–10.
20. Barrios V, Escobar C, de la Figuera M et al. High doses of lercanidipineare better tolerated than other dihydropyridines in hypertensivepatients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract 2008; 62 (5): 723–8.
21. Barbagallo M, Sangiorgi GB. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.
22. Nayler WG. Amlodipine. Berlin, 1995; p. 1–273.
23. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1): 73–80.
24. Robles NR, Romero B et al. Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs. Ren Fail 2010; 32 (2): 192–7.
25. Acanfora D, Trojano L, Gheorghiade M et al. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9 (5): S444–53.
26. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 3: S203–12.
27. Martinez ML, Castro MM, Rizzi E et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rate. Int J Clin Pract 2008: 65 (2): 723–8.
28. 31 Wu JR, Liou SF, Lin SW et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellurlar reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009; 59 (1): 48–56.
29. Sironi G, Colombo D, Greto L et al. Regional vasodilating effect of lercanidipine in dogs. ISHR XVI World Congress, 1998.
30. Sabbatini M, Tomassoni D, Amenta P. Influence of effect of treatment with Ca2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev 2001; 122 (8): 795–809.
31. De Ciuceis C, Salvetti M, Rossini C et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens 2014; 32 (2): 565–74.
32. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): S236–53.
33. Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double-blind pilot study. Curr Ther Res 2000; 61 (7): S477–87.
2. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press 1996; 5: S206–8.
3. Epstein M. Role of a third generation calcium antagonists in the management of hypertension. Drugs 1999; 57 (Suppl. 1): S1–10.
4. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26–30.
5. Barchielli M, Dolfini E, Farina P et al. Clinical pharmacokinetics of lercanidipine. J Cardiovascul Pharmacol 1997; 29 (Suppl. 2): S1–S15.
6. Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract no. P1.191]. J Hypertens 2000; 18 (Suppl. 2): S65.
7. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): S236–253.
8. McClellan KJ, Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.
9. Licher ThF, Cosebtino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998; 55 (4): S309–17.
10. Triggle DJ. Mechanisms of action of calcium channel antagonists. In: Calcium antagonists in clinical medicine. Ed. by M.Epstein. Philadelphia 1998; S1–26.
11. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovascul Pharmacol 1997; 29 (Suppl. 1): S19–S24.
12. Van Zweiten PA, Pfaffendorf M. Pharmacology of dihydropyridine calcium antagonists; Relatiomship between lipophilicity and pharmacodynamic response. J Hypertension 1993; 11 (Suppl. 6): S3–S11.
13. S’anchez A, Sayans R, Alvarez JL et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract №12]. Fourth European Meeting on Calcium Antagonists; 1999 Oct 27–29; Amsterdam.
14. Bang LM, Chapman TM, Goa KL. (New Zealand.) Лерканидипин: обзор эффективности в терапии артериальной терапии. Drugs 2003; 63 (22): 2449–72. / Bang LM, Chapman TM, Goa KL. (New Zealand.) Lerkanidipin: obzor effektivnosti v terapii arterial'noi terapii. Drugs 2003; 63 (22): 2449–72. [in Russian]
15. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): S95–100.
16. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31–5.
17. Romito R, Pansini MI, Perticone F et al. Comparative effect of oflercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): S249–53.
18. Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50–3.
19. James IGV, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16 (8): S605–10.
20. Barrios V, Escobar C, de la Figuera M et al. High doses of lercanidipineare better tolerated than other dihydropyridines in hypertensivepatients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract 2008; 62 (5): 723–8.
21. Barbagallo M, Sangiorgi GB. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.
22. Nayler WG. Amlodipine. Berlin, 1995; p. 1–273.
23. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1): 73–80.
24. Robles NR, Romero B et al. Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs. Ren Fail 2010; 32 (2): 192–7.
25. Acanfora D, Trojano L, Gheorghiade M et al. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9 (5): S444–53.
26. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 3: S203–12.
27. Martinez ML, Castro MM, Rizzi E et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rate. Int J Clin Pract 2008: 65 (2): 723–8.
28. 31 Wu JR, Liou SF, Lin SW et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellurlar reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009; 59 (1): 48–56.
29. Sironi G, Colombo D, Greto L et al. Regional vasodilating effect of lercanidipine in dogs. ISHR XVI World Congress, 1998.
30. Sabbatini M, Tomassoni D, Amenta P. Influence of effect of treatment with Ca2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev 2001; 122 (8): 795–809.
31. De Ciuceis C, Salvetti M, Rossini C et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens 2014; 32 (2): 565–74.
32. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): S236–53.
33. Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double-blind pilot study. Curr Ther Res 2000; 61 (7): S477–87.
2. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press 1996; 5: S206–8.
3. Epstein M. Role of a third generation calcium antagonists in the management of hypertension. Drugs 1999; 57 (Suppl. 1): S1–10.
4. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26–30.
5. Barchielli M, Dolfini E, Farina P et al. Clinical pharmacokinetics of lercanidipine. J Cardiovascul Pharmacol 1997; 29 (Suppl. 2): S1–S15.
6. Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract no. P1.191]. J Hypertens 2000; 18 (Suppl. 2): S65.
7. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): S236–253.
8. McClellan KJ, Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.
9. Licher ThF, Cosebtino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998; 55 (4): S309–17.
10. Triggle DJ. Mechanisms of action of calcium channel antagonists. In: Calcium antagonists in clinical medicine. Ed. by M.Epstein. Philadelphia 1998; S1–26.
11. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovascul Pharmacol 1997; 29 (Suppl. 1): S19–S24.
12. Van Zweiten PA, Pfaffendorf M. Pharmacology of dihydropyridine calcium antagonists; Relatiomship between lipophilicity and pharmacodynamic response. J Hypertension 1993; 11 (Suppl. 6): S3–S11.
13. S’anchez A, Sayans R, Alvarez JL et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract №12]. Fourth European Meeting on Calcium Antagonists; 1999 Oct 27–29; Amsterdam.
14. Bang LM, Chapman TM, Goa KL. (New Zealand.) Лерканидипин: обзор эффективности в терапии артериальной терапии. Drugs 2003; 63 (22): 2449–72. / Bang LM, Chapman TM, Goa KL. (New Zealand.) Lerkanidipin: obzor effektivnosti v terapii arterial'noi terapii. Drugs 2003; 63 (22): 2449–72. [in Russian]
15. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): S95–100.
16. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31–5.
17. Romito R, Pansini MI, Perticone F et al. Comparative effect of oflercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): S249–53.
18. Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50–3.
19. James IGV, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16 (8): S605–10.
20. Barrios V, Escobar C, de la Figuera M et al. High doses of lercanidipineare better tolerated than other dihydropyridines in hypertensivepatients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract 2008; 62 (5): 723–8.
21. Barbagallo M, Sangiorgi GB. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.
22. Nayler WG. Amlodipine. Berlin, 1995; p. 1–273.
23. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1): 73–80.
24. Robles NR, Romero B et al. Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs. Ren Fail 2010; 32 (2): 192–7.
25. Acanfora D, Trojano L, Gheorghiade M et al. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9 (5): S444–53.
26. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 3: S203–12.
27. Martinez ML, Castro MM, Rizzi E et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rate. Int J Clin Pract 2008: 65 (2): 723–8.
28. 31 Wu JR, Liou SF, Lin SW et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellurlar reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009; 59 (1): 48–56.
29. Sironi G, Colombo D, Greto L et al. Regional vasodilating effect of lercanidipine in dogs. ISHR XVI World Congress, 1998.
30. Sabbatini M, Tomassoni D, Amenta P. Influence of effect of treatment with Ca2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev 2001; 122 (8): 795–809.
31. De Ciuceis C, Salvetti M, Rossini C et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens 2014; 32 (2): 565–74.
32. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): S236–53.
33. Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double-blind pilot study. Curr Ther Res 2000; 61 (7): S477–87.
________________________________________________
2. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press 1996; 5: S206–8.
3. Epstein M. Role of a third generation calcium antagonists in the management of hypertension. Drugs 1999; 57 (Suppl. 1): S1–10.
4. Morisco C, Trimarco B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double blind controlled study. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S26–30.
5. Barchielli M, Dolfini E, Farina P et al. Clinical pharmacokinetics of lercanidipine. J Cardiovascul Pharmacol 1997; 29 (Suppl. 2): S1–S15.
6. Fogari R, Mugellini A, Corradi L et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients [abstract no. P1.191]. J Hypertens 2000; 18 (Suppl. 2): S65.
7. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): S236–253.
8. McClellan KJ, Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.
9. Licher ThF, Cosebtino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998; 55 (4): S309–17.
10. Triggle DJ. Mechanisms of action of calcium channel antagonists. In: Calcium antagonists in clinical medicine. Ed. by M.Epstein. Philadelphia 1998; S1–26.
11. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovascul Pharmacol 1997; 29 (Suppl. 1): S19–S24.
12. Van Zweiten PA, Pfaffendorf M. Pharmacology of dihydropyridine calcium antagonists; Relatiomship between lipophilicity and pharmacodynamic response. J Hypertension 1993; 11 (Suppl. 6): S3–S11.
13. S’anchez A, Sayans R, Alvarez JL et al. Left ventricular hypertrophy regression after a short antihypertensive treatment with lercanidipine vs. enalapril [abstract №12]. Fourth European Meeting on Calcium Antagonists; 1999 Oct 27–29; Amsterdam.
14. Bang LM, Chapman TM, Goa KL. (New Zealand.) Лерканидипин: обзор эффективности в терапии артериальной терапии. Drugs 2003; 63 (22): 2449–72. / Bang LM, Chapman TM, Goa KL. (New Zealand.) Lerkanidipin: obzor effektivnosti v terapii arterial'noi terapii. Drugs 2003; 63 (22): 2449–72. [in Russian]
15. Barrios V, Navarro A, Esteras A et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2): S95–100.
16. Policicchio D, Magliocca R, Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S31–5.
17. Romito R, Pansini MI, Perticone F et al. Comparative effect of oflercandipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercandipine in Adults (LEAD) study. J Clin Hypertens 2003; 5 (4): S249–53.
18. Paterna S, Licata A, Arnone S et al. Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl. 2): S50–3.
19. James IGV, Jones A, Davies P. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Hum Hypertens 2002; 16 (8): S605–10.
20. Barrios V, Escobar C, de la Figuera M et al. High doses of lercanidipineare better tolerated than other dihydropyridines in hypertensivepatients with metabolic syndrome: results from the TOLERANCE study. Int J Clin Pract 2008; 62 (5): 723–8.
21. Barbagallo M, Sangiorgi GB. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5): 375–9.
22. Nayler WG. Amlodipine. Berlin, 1995; p. 1–273.
23. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1): 73–80.
24. Robles NR, Romero B et al. Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs. Ren Fail 2010; 32 (2): 192–7.
25. Acanfora D, Trojano L, Gheorghiade M et al. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9 (5): S444–53.
26. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 3: S203–12.
27. Martinez ML, Castro MM, Rizzi E et al. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rate. Int J Clin Pract 2008: 65 (2): 723–8.
28. 31 Wu JR, Liou SF, Lin SW et al. Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellurlar reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol Res 2009; 59 (1): 48–56.
29. Sironi G, Colombo D, Greto L et al. Regional vasodilating effect of lercanidipine in dogs. ISHR XVI World Congress, 1998.
30. Sabbatini M, Tomassoni D, Amenta P. Influence of effect of treatment with Ca2+ antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech Ageing Dev 2001; 122 (8): 795–809.
31. De Ciuceis C, Salvetti M, Rossini C et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens 2014; 32 (2): 565–74.
32. Macchiarulo C, Pieri R, Mitolo DC et al. Antihypertensive effects of six calcium antagonists: evidence from Fourier analysis of 24-hour ambulatory blood pressure recordings. Curr Ther Res 2001; 62 (4): S236–53.
33. Cavallini A, Terzi G. Effects of antihypertensive therapy with lercanidipine and verapamil on cardiac electrical activity in patients with hypertension: a randomized, double-blind pilot study. Curr Ther Res 2000; 61 (7): S477–87.
Авторы
Т.Е.Морозова*, О.А.Вартанова
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*temorozova@gmail.com
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*temorozova@gmail.com
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*temorozova@gmail.com
________________________________________________
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*temorozova@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.